Q4 Financial Peaks and Valleys: Comparing Fortrea (NASDAQ:FTRE) With Other Drug Development Inputs & Services Companies

Q4 Review: Drug Development Inputs & Services Industry Standouts

With the fourth quarter earnings season wrapping up, it's an ideal moment to evaluate which companies in the drug development inputs and services sector—such as Fortrea (NASDAQ:FTRE)—excelled and which lagged behind.

Industry Overview

Firms that provide drug development inputs and services are essential to the pharmaceutical and biotech industries. They offer critical support for drug discovery, preclinical research, and manufacturing, ensuring steady demand as pharmaceutical companies frequently outsource these specialized tasks through medium- and long-term contracts. However, this sector faces challenges, including significant capital needs, reliance on a limited number of clients, and exposure to changes in R&D spending or regulatory shifts. Looking ahead, the industry is set to benefit from increased investments in biologics, cell and gene therapies, and precision medicine, all of which require advanced tools and services. The ongoing trend toward outsourcing for greater flexibility and cost savings further supports growth. On the downside, the sector must contend with pricing pressures as healthcare cost containment remains a priority, and evolving regulations could potentially slow innovation or dampen client activity.

Q4 Performance Snapshot

Among the eight companies in this space that we monitor, fourth quarter results were mixed. Collectively, their revenues surpassed analyst forecasts by 1.5%.

Despite these revenue beats, share prices have struggled, with the group’s average stock price declining 8.7% since their most recent earnings announcements.

Q4’s Weakest Performer: Fortrea (NASDAQ:FTRE)

Fortrea, which separated from Labcorp in 2023 to focus solely on clinical research services, operates as a contract research organization. It partners with pharmaceutical, biotech, and medical device firms to facilitate clinical trials and bring new products to market.

For the quarter, Fortrea posted revenues of $660.5 million—a 5.2% decrease compared to the previous year and 0.9% below analyst expectations. The company’s full-year revenue guidance also fell well short of forecasts, and earnings per share missed estimates by a wide margin.

“We closed out 2025 with strong fourth quarter results, as our team’s dedication to commercial, operational, and financial excellence becomes ingrained in our culture,” commented Anshul Thakral, Fortrea’s CEO.

Fortrea delivered the lowest performance relative to analyst expectations, experienced the slowest revenue growth, and issued the weakest full-year guidance among its peers. Interestingly, despite these results, the stock has risen 2.3% since the earnings release and is currently trading at $10.57.

Q4’s Top Performer: Medpace (NASDAQ:MEDP)

Established in 1992 as a science-driven alternative to traditional contract research organizations, Medpace offers outsourced clinical trial management and research services to support the development of new therapies for pharmaceutical, biotech, and medical device companies.

Medpace reported revenues of $708.5 million, marking a 32% year-over-year increase and surpassing analyst projections by 3.3%. The company not only exceeded organic revenue expectations but also delivered a strong beat on full-year EPS guidance.

Medpace achieved the highest revenue growth and the largest beat of analyst estimates among its competitors. Despite this, the market reacted negatively, with the stock dropping 12.7% since the earnings announcement. Shares are currently priced at $463.

Azenta (NASDAQ:AZTA)

Azenta specializes in safeguarding some of the most valuable assets in medicine, offering biological sample management, storage, and genomic services to help pharmaceutical and biotech companies preserve and analyze vital research materials.

For the quarter, Azenta’s revenue was $148.6 million, unchanged from the previous year but 1.1% above analyst expectations. However, the company missed EPS estimates by a significant margin, making it a weaker quarter overall.

Following the results, Azenta’s stock has declined 33.5% and is now trading at $24.54.

UFP Technologies (NASDAQ:UFPT)

With a history dating back to 1963, UFP Technologies is known for its expertise in specialized materials and precision manufacturing. The company creates custom solutions for medical devices, sterile packaging, and other highly engineered products for healthcare and industrial clients.

UFP Technologies reported revenues of $148.9 million, a 3.4% year-over-year increase, aligning with analyst forecasts. The quarter was solid overall, with EPS beating expectations and revenue meeting projections.

Since the earnings release, the stock has fallen 15.6% and is currently valued at $203.01.

Charles River Laboratories (NYSE:CRL)

Founded in 1947 along the Charles River in Massachusetts, Charles River Laboratories provides non-clinical drug development services, research models, and manufacturing support for pharmaceutical and biotech companies.

Charles River Laboratories posted revenues of $994.2 million, flat year over year but 1.4% ahead of analyst expectations. The company narrowly beat revenue estimates, making it a satisfactory quarter overall.

The stock has gained 10.9% since the earnings announcement and is now trading at $175.77.

Discover High-Quality Investment Opportunities

Looking for companies with strong fundamentals? Explore our Hidden Gem Stocks and add them to your watchlist. These businesses are well-positioned for growth, regardless of political or economic shifts.

The StockStory analyst team—comprised of experienced professional investors—leverages quantitative analysis and automation to deliver timely, high-quality market insights.